SGO not soft on morcellation: Risks and benefits must be weighed

The Lancet Oncology

Volumn 15, Issue 4, 2014, Pages

  Goff, Barbara A ^a  

^a Society of Gynecologic Oncologists   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD TRANSFUSION; CANCER PROGNOSIS; CANCER RISK; CANCER SURGERY; CLINICAL EFFECTIVENESS; HUMAN; HYSTERECTOMY; LAPAROTOMY; LENGTH OF STAY; LETTER; MEDICAL SOCIETY; MORBIDITY; ORGANIZATIONAL DOWNSIZING; ORGANIZATIONAL EFFICIENCY; OUTCOME ASSESSMENT; PATIENT SAFETY; POSTOPERATIVE PAIN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SURGICAL INFECTION; SURGICAL RISK; VEIN THROMBOSIS;

FEMALE; HUMANS; HYSTERECTOMY; LEIOMYOMA; LEIOMYOSARCOMA; NEOPLASM SEEDING; PATIENT SAFETY; UTERINE NEOPLASMS;

EID: 84897039489     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70075-0     Document Type: Letter

References (2)

1. Patient safety must be a priority in all aspects of care. Lancet Oncol 2014, 15:123. The Lancet Oncology.
2. Position statement on morcellation Society of Gynecologic Oncology, (accessed on March 17, 2014). https://www.sgo.org/newsroom/position-statements-2/morcellation/.